Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
2011-11-23 | Proximagen (UK) Altacor (UK) | PRX00933, the lead compound from Proximagen’s 5HT2c programme | glaucoma | R&D |
Ophtalmological diseases | R&D agreement |
2011-11-22 | OctoPlus (The Netherlands) undisclosed partner | Additional drug product | undisclosed
|
Manufacturing Production |
||
2011-11-18 | Shire (UK) Shionogi (Japan) | certain of Shire’s Attention Deficit Hyperactivity Disorder (ADHD) medicines | Attention deficit hyperactivity disorder (ADHD) | development |
Mental diseases - Psychiatric diseases | Development agreement |
2011-11-17 | Cenix BioScience (Germany) SYGNIS Bioscience (Germany) | R&D |
CNS diseases | R&D agreement | ||
2011-11-16 | Genzyme (USA - MA), a Sanofi company (France) Cystic Fibrosis Foundation Therapeutics (USA) | new cystic fibrosis drugs | cystic fibrosis | research - R&D | Rare diseases - Genetic diseases | R&D agreement |
2011-11-15 | UCB (Belgium) Parexel (USA) PRA (USA) | clinical development services | clinical development |
Services contract | ||
2011-11-15 | Almirall (Spain) Biofocus, a Galapagos Company (UK - Belgium) | new hit compounds against key targets of interest to Almirall | respiratory and inflammatory conditions | R&D |
Respiratory diseases - Inflammatory diseases | R&D agreement |
2011-11-09 | Ablynx (Belgium) Merck Serono (Germany) | Nanobodies® against two targets in osteoarthritis | osteoarthritis | R&D |
Rheumatic diseases - Inflammatory diseases – Bone diseases | R&D agreement |
2011-11-09 | Dako (Denmark) BMS (USA) | pharmacodiagnostic tests intended to identify patients more likely to benefit from treatment with investigational drug candidates under development by Bristol-Myers Squibb | development
|
Development agreement | ||
2011-11-08 | ADx NeuroSciences (Belgium) KU Leuven (Belgium) | antibodies used in dementia diagnosis | development
|
Neurodegenerative diseases | Development agreement | |
2011-11-07 | Antitope (UK) Therapure Biopharma (Canada) | therapeutic monoclonal antibodies | R&D |
R&D agreement | ||
2011-11-07 | Oxford Gene Technology (UK) Abcodia (UK) | pancreatic cancer specific biomarkers | pancreatic cancer | development |
Cancer - Oncology | Development agreement |
2011-11-03 | Ark Therapeutics (UK) University of Glasgow's Institute of Cardiovascular and Medical Sciences (UK) | adenoviral vector expressing TIMP3 gene | vein graft failure associated with coronary artery bypass surgery | manufacturing |
Cardiovascular diseases | Production agreement |
2011-11-02 | MorphoSys (Germany) Shionogi (Japan) | HuCAL antibody technology and additional proprietary technology modules for research in drug discovery | R&D licensing |
R&D agreement | ||
2011-11-02 | Exonhit (France) Allergan (USA) | new drugs for the treatment of neurodegenerative diseases, pain and ophthalmology | R&D development commercialisation |
Neurodegenerative diseases - Ophtalmological diseases - CNS diseases | R&D agreement | |
2011-11-02 | Illumina (USA) Siemens Healthcare Diagnostics (USA), subsidiary of Siemens AG (Germany) | next-generation sequencing for the rapid, accurate identification of patients\' infectious disease states and potential treatment paths. | development |
Infectious diseases | Development agreement | |
2011-11-02 | BioQuanta (France) Gentronix (UK) | Mitoxis® functional metabolomics platform | distribution |
Commercialisation agreement | ||
2011-11-01 | GSK (UK) Alnylam Pharmaceuticals (USA - MA) | VaxiRNA® technology | R&D |
Infectious diseases | R&D agreement | |
2011-10-31 | Oxford BioMedica (UK) Mayo Clinic (USA) | gene therapy using LentiVector® gene delivery technology expressing a COX-2 gene and a PGF-2alpha receptor gene | R&D |
Ophtalmologic diseases | R&D agreement | |
2011-10-30 | Antitope (UK) Kolltan Pharmaceuticals (USA) | therapeutic monoclonal antibodies for the treatment of cancer | cancer | R&D |
Cancer - Oncology | R&D agreement |